Skip to main content

Iman Mohammadi

Author Biography

Iman Mohammadi, PhD

Director, Research Science and Advanced Analytics

Iman leads, designs, and executes healthcare economics and advanced analytics projects and solutions. He conducts high-level analytic modeling to support healthcare, payer, and life sciences customers make optimal business decisions aimed at improving quality and lowering costs.

With experience in predictive modeling and advanced statistical techniques and a deep understanding of healthcare processes and challenges including market access, cardiology and oncology treatment patterns, real word evidence generation, health economics and outcomes research, healthcare coverage models, and episode-based oncology care models, Man provides insights, solutions, and decision-making tools for Inovalon clients.

Prior to joining Inovalon, Iman was a researcher and instructor at Indiana University. He focused on improving healthcare systems and patient centered outcomes research. Specifically, he used electronic health record data from various healthcare systems to develop predictive and simulation models for improving access to care for underserved populations. He taught undergrad and grad level courses, such as Informatics Project Management and Health Information Standards and Terminologies, at Indiana University.

Iman has a PhD in health informatics from Indiana University and an MS in biomedical engineering from Purdue University.

Authored Content

Filter

May 7, 2023
Presentation

Characteristics, Healthcare Resource Utilization, Cost, and Quality Outcomes of Medicare Beneficiaries While Commercially Insured Before and After Transition to Medicare Advantage or Traditional Medicare Fee-for-Service

Accepted for presentation at ISPOR 2023. Findings available upon request. Contact us for more information.
May 3, 2023
Poster Presentation

Characteristics, Healthcare Resource Utilization, Cost, and Quality Outcomes of Medicare Beneficiaries While Commercially Insured Before and After Transition to Medicare Advantage or Traditional Medicare Fee-for-Service

Boris Vabson, Zulkarnain Pulungan, Zarek Brot-Goldberg, Yalun Su, Iman Mohammadi, Barton Jones, Christie Teigland
This study provides a first look at demographic, clinical, and social risk characteristics of individuals who select MA versus FFS while covered by commercial insurance prior to turning age 65 and compares healthcare outcomes before and after enrolling.
May 31, 2022
Presentation

Characteristics and Treatment Patterns in Medicare Patients Newly Diagnosed with Schizophrenia with Traditional Fee-For Service Versus Private Medicare Advantage Insurance Coverage

Teigland C, Kim S, Mohammadi I, Agatep B, Boskovic DH
Accepted for presentation at American Society of Clinical Psychopharmacology 2022 Annual Meeting. Findings available upon request. Contact us for more information.
May 15, 2022
Presentation

Treatment Patterns in Patients Newly Diagnosed with Schizophrenia with Commercial Versus Medicaid Insurance Coverage

Teigland C, Kim S, Mohammadi I, Agatep B, Boskovic DH
Schizophrenia is a serious mental disorder that requires lifelong treatment. Early treatment can help get symptoms under control before serious complications develop (e.g., suicide, anxiety disorder, aggressive behavior, depression, alcohol/drug abuse, inability to work, financial and health/medical problems). This research evaluated treatment patterns in patients newly diagnosed with schizophrenia in two populations with commercial versus Medicaid insurance.
May 15, 2022
Presentation

Risk Factors for Recurrences of Clostridioides Difficile Infection in the Medicare Population Age 65+ Years

Amin A, Guo A, Teigland C, Mohammadi I, Schablik J, Reveles K
Clostridioides difficile infection (CDI) recurrences are associated with substantial clinical and economic burden including high mortality and high hospitalization cost. We analyzed recently available 100% Medicare Fee-for-Service (FFS) claims to assess recurrence and identify risk factors for patients experiencing 1, 2, and 3+ recurrences of CDI (rCDI) to inform CDI patient management.
May 15, 2022
Presentation

Contemporary Total Cost of Care Among Medicare Patients with Primary and Recurrent Clostridioides Difficile Infection

Amin A, Guo A, Teigland C, Mohammadi I, Schablik J, Reveles K
We evaluated mortality and total healthcare costs among contemporary Medicare patients with primary CDI (pCDI) and recurrent CDI (rCDI), as well as the main drivers of the costs.
May 15, 2022
Presentation

Contemporary Total Cost of Care Among Medicare Patients with Primary and Recurrent Clostridioides Difficile Infection

Amin A, Guo A, Teigland C, Mohammadi I, Schablik J, Reveles K
Accepted for presentation at ISPOR 2022. Findings available upon request. Contact us for more information.
May 15, 2022
Presentation

Risk Factors for Recurrences of Clostridioides Difficile Infection in the Medicare Population Age 65+ Years

Amin A, Guo A, Teigland C, Mohammadi I, Schablik J, Reveles K
Accepted for presentation at ISPOR 2022. Findings available upon request. Contact us for more information.